|Previous Section||Index||Home Page|
Mr. Bradshaw: This information is not held centrally. It is for the local national health service to determine how best to provide services for their local communities. My hon. Friend may wish to contact Jan Stubbings, chief executive of Gloucestershire primary care trust directly, in order for her to deal with the issues raised.
Dawn Primarolo: Pathogen inactivation is currently carried out for a limited number of blood products, not all of which are centrally procured, and it is not therefore possible to estimate the costs to the NHS. However, the Advisory Committee on the Safety of Blood, Tissues and Organs will be undertaking a comprehensive review of pathogen inactivation for blood products in 2009. This will include a full assessment of the costs of interventions and cost-benefit analysis.
Mr. Lansley: To ask the Secretary of State for Health with reference to his Department's Cancer Reform Strategy published in December 2007, if he will place in the Library the data from which the graphs on pages (a) 88, (b) 120 and (c) 121 were drawn. 
Ann Keen: The data represented in the graph on page 88 of the Cancer Reform Strategy (Proportion of patients in England and Wales in the various age bands who received any active anti-cancer treatment) are set out in the following table. This table has been taken from page 34 (figure 8.4.10) of the National Lung Cancer Audit Report 2006. The table shows any active anti-cancer treatments received by lung cancer patients first seen in 2006 by age groups for all lung cancers, excluding small cell carcinoma.
|Any anti-cancer treatment by age groupall lung cancers excluding small cell carcinoma|
A table setting out the data represented in the graph on page 120 of the Cancer Reform Strategy (Spending on cancer in 2006-07 as percentage total of primary care trust (PCT) programme spend) has been placed in the Library. The graph is based on programme budgeting data, collected as part of the annual accounts process. PCT level programme budgeting data are published annually in the form of an interactive Excel spreadsheet on the Department of Health's website at:
A table setting out the data represented in the bar chart on page 121 of the Cancer Reform Strategy (Estimated cost per head of NICE-approved cancer drugs used in hospitals in January to June 2005, by cancer network) has been placed in the Library. This analysis was carried out by the Department and the calculations are based on information on volumes of NICE-approved cancer drugs dispensed (from IMS Health (an international consulting and data services company) and cancer network data) and the lowest list prices of those drugs.
Dawn Primarolo: Information on all Creutzfeldt-Jakob Disease (CJD) deaths in the United Kingdom collected since the establishment of the National Creutzfeldt-Jakob Disease Surveillance Unit in 1990 is in the following table:
|CJD in the United Kingdom (by calendar year)data to 6 October 2008|
|Referrals of suspect CJD||Deaths of definite and probable CJD|
|Year||Referrals||Year||Sporadic||Iatrogenic||Familial||Gertmann Straussler Scheinker Disease||Variant Creutzfeldt Jakob Disease||Total d eaths|
National Creutzfeldt-Jakob Disease Surveillance Unit
|Next Section||Index||Home Page|